Dec. 19, 2019: Often-insufficient CD4 and viral load testing for women; factors affecting syphilis incidence among women with HIV; STI testing rates among people with HIV; the effect of benzodiazepines on neurocognition.
Common Antidepressant Reduces Meth Use and High-Risk Sexual Behavior for Gay and Bisexual Men and Transgender Women
Could this give hope to people struggling with crystal meth addiction?
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
This population is under-represented in HIV data, and few prevention or treatment interventions exist to support them. A new meta-analysis hopes to paint a picture of what's needed.
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
Communities Should Be Involved in Research. Here Are Some Key Insights on Good Participatory Practice.
Increasingly, researchers are looking for ways to involve communities not just by participating in trials, but by helping shape these projects. But, how do you go about making sure affected communities are at the table?
Four recent studies in JAIDS chiefly focused on PrEP provision to cisgender women and gay and bisexual men.
Experts Flummoxed By Conflicting New Data on STIs, HIV, and Long-Term Contraception in Sub-Saharan Africa
ECHO trial results and follow-up studies find unexpectedly low rates of some STIs among users of certain long-term hormonal contraceptives. They also find high HIV rates (unrelated to the contraceptives) that suggest considerable value for PrEP integration.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
July 11, 2019: Seroconversion while on long-acting contraceptives; cardiovascular risk in people with HIV; suboptimal testing in high-prevalence U.S. areas; E/C/F/TAF may be suitable for PEP.